La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MiMedx Group Crescita futura

Future criteri di controllo 1/6

Si prevede che gli utili di MiMedx Group diminuiranno del 7% all'anno, mentre si prevede che il fatturato annuo crescerà del 10% all'anno. Si prevede che l'EPS diminuirà del 14.2% all'anno.

Informazioni chiave

-7.0%

Tasso di crescita degli utili

-14.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.3%
Tasso di crescita dei ricavi	10.0%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	06 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:MDXG - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	439	67	N/A	98	2
12/31/2025	382	48	65	77	5
12/31/2024	343	42	54	56	5
6/30/2024	340	79	48	51	N/A
3/31/2024	335	68	34	37	N/A
12/31/2023	321	56	25	27	N/A
9/30/2023	309	19	8	11	N/A
6/30/2023	295	2	-4	-1	N/A
3/31/2023	281	-18	-15	-12	N/A
12/31/2022	268	-27	-21	-18	N/A
9/30/2022	261	-34	-17	-16	N/A
6/30/2022	256	-28	-12	-10	N/A
3/31/2022	258	-19	-7	-6	N/A
12/31/2021	242	-18	-5	-2	N/A
9/30/2021	260	-35	-14	-9	N/A
6/30/2021	261	-83	-25	-20	N/A
3/31/2021	246	-88	-30	-25	N/A
12/31/2020	248	-83	-35	-30	N/A
9/30/2020	256	-73	-46	-43	N/A
6/30/2020	281	-8	-44	-42	N/A
3/31/2020	294	-17	-39	-36	N/A
12/31/2019	299	-26	-42	-39	N/A
9/30/2019	315	-54	-18	-15	N/A
6/30/2019	314	-67	-14	-8	N/A
3/31/2019	342	-48	3	10	N/A
12/31/2018	359	-30	26	36	N/A
9/30/2018	354	41	46	55	N/A
6/30/2018	352	59	61	70	N/A
3/31/2018	333	65	N/A	62	N/A
12/31/2017	321	65	N/A	63	N/A
9/30/2017	303	35	N/A	59	N/A
6/30/2017	283	21	N/A	44	N/A
3/31/2017	264	15	N/A	37	N/A
12/31/2016	222	0	N/A	24	N/A
9/30/2016	227	20	N/A	14	N/A
6/30/2016	212	23	N/A	18	N/A
3/31/2016	200	27	N/A	14	N/A
12/31/2015	187	29	N/A	19	N/A
9/30/2015	175	20	N/A	23	N/A
6/30/2015	160	17	N/A	24	N/A
3/31/2015	139	11	N/A	23	N/A
12/31/2014	118	6	N/A	17	N/A
9/30/2014	97	1	N/A	9	N/A
6/30/2014	79	-3	N/A	2	N/A
3/31/2014	67	-3	N/A	0	N/A
12/31/2013	59	-4	N/A	0	N/A
9/30/2013	52	-4	N/A	-2	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di MDXG diminuiranno nei prossimi 3 anni ( -7% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di MDXG diminuiranno nei prossimi 3 anni ( -7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MDXG diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MDXG ( 10% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MDXG ( 10% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di MDXG è previsto essere elevato tra 3 anni

MiMedx Group Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 10%

MiMedx Group, Inc. Provides Sales Guidance for the Full Year of 2024

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Price target increased by 8.0% to US$10.17

Recent updates

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

MiMedx Group, Inc. Provides Sales Guidance for the Full Year of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MiMedx Group, Inc. Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature- Scientific Reports

MiMedx Group, Inc. to Report Q2, 2024 Results on Jul 31, 2024

MiMedx Group, Inc. Announces the Appointment of Kim Moller to Chief Commercial Officer

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range